The mortality rate due to prostate malignant neoplasms in Australia has experienced variations over the past years, standing at 3.71 thousand male deaths in 2023. Initial fluctuations were observed with slight declines and increases from 2013 to 2015, followed by a more pronounced rise in 2019. The year-on-year variations over the last two years were 1.3% in 2022 and 1.25% in 2023, indicating a modest but consistent upward trend. The five-year compound annual growth rate (CAGR) from 2018 to 2023 was 2.6%, reflecting a steady increase.
Looking forward, forecasted data suggests that the mortality rate will continue to rise, reaching 3.94 thousand male deaths by 2028. Although the forecasted five-year CAGR is 0.93%, lower than the recent historical trend, this still represents a notable increase with an overall growth rate of 4.76% for the period.
Trends to watch for in the future include advancements in early detection and treatment, potential changes in healthcare policies, the impact of lifestyle modifications, and new medical research outcomes which could influence prostate cancer mortality rates.
